Glucotrack (NASDAQ:GCTK) has announced positive final results from its first-in-human clinical study for its innovative Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association's 85th Scientific Sessions. The study demonstrated excellent accuracy with a MARD of 7.7% across 122 matched pairs and a 99% data capture rate, with no serious adverse events.
The implantable CBGM technology measures glucose directly from blood rather than interstitial fluid, eliminating typical lag time associated with traditional monitors. The study, conducted in Brazil from December 2024 to January 2025, included ten Type 1 or Type 2 diabetes patients. Analysis showed 92% of measurements in the green zone of the Diabetes Technology Society Error Grid, indicating high clinical accuracy.
The company plans to initiate a long-term early feasibility study in Q3 2025. The CBGM system is designed for a three-year sensor life with no on-body wearable component and minimal calibration requirements.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.